Biomarker testing for ovarian cancer: clinical utility of multiplex assays - Test2 - elhamkhani - TriplyDB

Biomarker testing for ovarian cancer: clinical utility of multiplex assays

Biomarker testing for ovarian cancer: clinical utility of multiplex assays

http://www.wikidata.org/entity/Q36897149

about

Translational progress on tumor biomarkers MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer In 2014, can we do better than CA125 in the early detection of ovarian cancer?Endocannabinoids as biomarkers of human reproduction Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics ROR1 expression correlated with poor clinical outcome in human ovarian cancer Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay.Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.Secretome Identifies Tenascin-X as a Potent Marker of Ovarian Cancer.The influence of neighborhood socioeconomic status and race on survival from ovarian cancer: a population-based analysis of Cook County, Illinois.Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.A microfluidic ExoSearch chip for multiplexed exosome detection towards blood-based ovarian cancer diagnosis.Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors The role of miRNAs in cancer: from pathogenesis to therapeutic implications.Translational Research and Plasma Proteomic in Cancer.The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.Assessment of serum angiotensin-converting enzyme in patients with epithelial ovarian cancer.VSV based virotherapy in ovarian cancer: the past, the present and …future?Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.A joint model based on longitudinal CA125 in ovarian cancer to predict recurrence.Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?Serum Biomarker Based Algorithms in Diagnosis of Ovarian Cancer: A Review

P2860

Q26777676-21953288-0CB8-4B61-83FE-8DF4A8685BC1 Q26822743-8CC946DF-3877-4FBA-A237-014CB801FDFA Q26825152-712052D2-B921-4383-AD03-3BB99F29BD43 Q27024033-76D3A999-D946-470D-B2D5-6ACB1BEE304E Q30421664-836720F5-151E-45C7-BBD9-FD1B10F1D7FE Q33942010-BA91A593-A37B-4D10-BEFF-12F8D3A35ADF Q34761258-3A3FCE31-848B-4156-97EA-A85CE000251F Q35208879-C3C24964-2C3B-4E3A-BAB8-DBDF293CDB79 Q35661217-B3D47815-D084-4710-A53E-6A29F13894D1 Q35668872-43E9A400-32F6-426B-AF82-6911A7EA1251 Q35828154-85250283-91BF-4F10-A530-6F104080D45F Q36169039-360FE745-5AAC-44FA-88B4-8E5235D19E93 Q36510465-DCC2EB23-E396-4574-8A13-1B1F89779E6D Q37520401-63C6AF14-90E9-4A39-B857-E69CCC744AC6 Q37643626-F3C11972-5FB2-4773-8F94-D7DBAC0D0517 Q38221290-D0A98312-0019-4414-99F1-5A50A7DEF2F2 Q38610869-1CAA2012-78B0-428D-96C5-C0B5A02FA342 Q38975570-AE6A977B-DF37-41DD-B3A4-B247A1DF66A9 Q39037577-74C5E98A-B0F8-489F-994E-91D0832CA576 Q41441101-C131F61F-92BC-4FC6-A7F8-874848752EF3 Q41512697-1F2ED02D-07BD-4A82-A790-17C87515E890 Q48070530-7E90BBBF-E7B4-468A-AAF1-1682232A843B Q48594906-602F7396-359C-4D09-9C3E-F6ECC2B62A94 Q52941950-CD06A1DB-1898-4409-B282-AB4C116F5871 Q55280402-0D10AF96-C2AF-4C53-AE54-DFC24E13C639 Q57487046-53E8DE3F-616B-411B-8817-F4584FC58109

P2860

Biomarker testing for ovarian cancer: clinical utility of multiplex assays

http://www.wikidata.org/entity/Q36897149

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Biomarker testing for ovarian cancer: clinical utility of multiplex assays

@en

type

label

Biomarker testing for ovarian cancer: clinical utility of multiplex assays

@en

prefLabel

Biomarker testing for ovarian cancer: clinical utility of multiplex assays

@en

P1433

Q36897149-811A7FD9-8676-4BDF-BE08-E596484BE1EF

P1476

Q36897149-7AEC3935-A108-45F3-9190-90164C50F45D

P2093

Q36897149-5D96A5BD-16C1-447A-9757-216A3552AAAD

Q36897149-DC42A23E-C8AC-42E8-82D3-9EA6AE6D6BA0

P2860

Q36897149-02352CF8-18F8-46F0-8843-C87C4CC672AE

Q36897149-07D00D89-B5A3-47F7-8FF2-87D83B7392DE

Q36897149-0A88AF45-4F09-4625-8C74-47C8AF4FD162

Q36897149-0F944AAB-A625-458E-BEEB-82AEFDB327E6

Q36897149-12C4F7CD-54DD-4336-8605-AABA90703CA9

Q36897149-14C1D0FB-D7CC-4861-AEFF-2884516E547F

Q36897149-165534C1-5010-42E8-ABCB-4203FA79F9AF

Q36897149-215C88CE-FEDE-4C62-A2BE-7911EF054D9C

Q36897149-23B156A3-37D1-466F-AC56-1D99FAA18D7D

Q36897149-34297BF3-96E8-4B7C-A39D-721E3ACA0335

P2888

Q36897149-8B0D03D1-041D-457B-84EE-47A703F09A18

P304

Q36897149-68D20117-D095-4C1D-B891-0D46189E7BB1

P31

Q36897149-472B0B21-B3EA-410D-95AF-578698612BD1

P356

Q36897149-4ED880D1-FCB2-4E0C-9478-E56BABC1E4D6

P433

Q36897149-5A41DE4F-ABE5-4003-A4DD-3CC412C658E3

P478

Q36897149-E6F030F1-3279-456B-9C66-C91A9B7683B2

P577

Q36897149-39BA2757-E9E8-4477-B84C-A3B5F63A64A5

P698

Q36897149-A73AFF4C-1501-492E-8678-F775BA14095D

P921

Q36897149-89ECAE5D-BEBC-4F47-91F4-D24AACF877FD

Q36897149-ADF5039D-05E3-4AEE-9DD6-D18970B5666B

P932

Q36897149-BAECC691-3CF3-4A21-8E33-335BDC14BC92

P356

S40291-013-0027-6

P1433

Molecular Diagnosis and Therapy

P1476

Biomarker testing for ovarian cancer: clinical utility of multiplex assays

@en

P2093

Anna E Lokshin

http://www.w3.org/2001/XMLSchema#string

Brian M Nolen

http://www.w3.org/2001/XMLSchema#string

P2860

Results from four rounds of ovarian cancer screening in a randomized trial

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

Effect of Screening on Ovarian Cancer Mortality

Tissue Kim-1 and urinary clusterin as early indicators of cisplatin-induced acute kidney injury in rats

Development and preliminary evaluation of a multivariate index assay for ovarian cancer.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Validation of candidate serum ovarian cancer biomarkers for early detection.

Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study

Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.

Development of a multimarker assay for early detection of ovarian cancer.

P2888

s40291-013-0027-6

P304

139-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40291-013-0027-6

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23552992

http://www.w3.org/2001/XMLSchema#string

P921

P932

3670781

http://www.w3.org/2001/XMLSchema#string